An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor.
about
Anthrax prophylaxis: recent advances and future directionsNew developments in vaccines, inhibitors of anthrax toxins, and antibiotic therapeutics for Bacillus anthracis.Identification of peptide sequences as a measure of Anthrax vaccine stability during storage.CD4+ T-cell immunity to the Burkholderia pseudomallei ABC transporter LolC in melioidosisAnthrax lethal factor as an immune target in humans and transgenic mice and the impact of HLA polymorphism on CD4+ T cell immunityQuantitative Determination of Lethal Toxin Proteins in Culture Supernatant of Human Live Anthrax Vaccine Bacillus anthracis A16R.Neutralizing monoclonal antibodies against ricin's enzymatic subunit interfere with protein disulfide isomerase-mediated reduction of ricin holotoxin in vitro.Anthrax lethal toxin and the induction of CD4 T cell immunity.Anthrax vaccines: present status and future prospects.Generation of a novel chimeric PALFn antigen of Bacillus anthracis and its immunological characterization in mouse model.Anthrax Vaccine Precipitated induces Edema Toxin-neutralizing, Edema Factor-specific antibodies in human recipients.Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated.Evaluation of clinical and serological findings for diagnosis of cutaneous anthrax infection after an outbreak.A bivalent protein r-PB, comprising PA and BclA immunodominant regions for comprehensive protection against Bacillus anthracis.Cloning, expression and purification of binding domains of lethal factor and protective antigen of Bacillus anthracis in Escherichia coli and evaluation of their related murine antibody.Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia.
P2860
Q26781366-3C318D3C-3D68-485F-915C-20E1CA02B4C1Q34066161-079BE834-CA84-429D-8478-15D50F25B662Q34290957-1CB476E0-8786-4951-AD54-899489868194Q35138054-B05F24E6-E50F-4A06-9D7E-45AE865FD687Q35161514-C1E7B8CF-A489-4484-8C73-8D2C551E5338Q36735532-E7703DF2-1871-43EB-8D91-39D69BBDC850Q37120906-086CD1E7-E306-4644-8301-A0E88AB126AFQ38060730-E9787BE8-5A2E-451F-9D8B-7DCF8EC15F38Q38132268-CBC7D223-61C0-49DF-8E70-1DB010FCCAE7Q38760574-F3B80C12-4741-4FEC-AA94-36B473F1173DQ40064017-CAEA404A-C57E-4614-A4A1-4B86984C5B3CQ40213025-D5BBDA82-6832-41ED-9A35-3F80F2729340Q40376368-3450E38F-E071-4D4B-B1ED-F7025395BD6EQ54217728-A464B39D-4A87-4CC1-8784-CF35A2429F13Q54296845-46464432-F3F1-4E7E-BA2B-4F1F787FDB31Q55361721-1D0F01F8-C075-42B1-8DCB-8686897B25D1
P2860
An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
An anthrax subunit vaccine can ...... ive antigen and lethal factor.
@ast
An anthrax subunit vaccine can ...... ive antigen and lethal factor.
@en
An anthrax subunit vaccine can ...... ive antigen and lethal factor.
@nl
type
label
An anthrax subunit vaccine can ...... ive antigen and lethal factor.
@ast
An anthrax subunit vaccine can ...... ive antigen and lethal factor.
@en
An anthrax subunit vaccine can ...... ive antigen and lethal factor.
@nl
prefLabel
An anthrax subunit vaccine can ...... ive antigen and lethal factor.
@ast
An anthrax subunit vaccine can ...... ive antigen and lethal factor.
@en
An anthrax subunit vaccine can ...... ive antigen and lethal factor.
@nl
P2093
P2860
P50
P1433
P1476
An anthrax subunit vaccine can ...... tive antigen and lethal factor
@en
P2093
Brendan N Neeson
Dominic C Jenner
Helen C Flick-Smith
Helen S Atkins
James P Nataro
Liliana Rodriguez
Marcela F Pasetti
Stephen Moore
Theresa B Huwar
P2860
P304
P356
10.1016/J.VACCINE.2010.07.075
P407
P577
2010-08-04T00:00:00Z